New hope for AML patients: gentler drug combo could replace harsh chemo

NCT ID NCT07664839

Not yet recruiting Disease control Sponsor: Shen yang Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new drug combination (venetoclax plus azacitidine) against standard chemotherapy for adults with a specific type of acute myeloid leukemia (AML) that has NPM1 or IDH mutations. About 148 people will be randomly assigned to one of the two treatments. The main goal is to see if the new combo works as well as standard chemo at achieving remission, while also tracking side effects and long-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax combined with azacitidine
What this could lead to: If it works, this could offer a less intensive treatment option for certain AML patients, potentially with fewer side effects than standard chemotherapy.
What could go wrong: This is a phase 2 trial with only 148 participants, so results are preliminary. The new regimen may not be as effective as standard chemo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA IDH1 MUTATION IDH2 MUTATION NPM1 MUTATION

Contacts and locations

Locations

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.